Licensed to Scale - Healthcare Licensing, IP Commercialisation & Cross-Border Market Access Capital Roundtable
Licensed to Scale - A closed-door capital conversation on healthcare licensing, IP commercialisation, and cross-border market access.
Some of the most valuable transactions in healthcare never make the headlines. No IPO. No acquisition announcement. Just a licensing agreement- and a revenue stream that compounds quietly across geographies for years.
Pharmaceutical molecules. Medical device technology. Health-tech IP. Bioscience platforms. Diagnostic protocols. The full spectrum of healthcare innovation can be licensed, commercialised, and taken to market without the founder ever raising a traditional round or the investor ever taking a board seat.
It is one of the most capital-efficient paths to global market access in healthcare and one of the least institutionally organised.
That is the gap Licensed to Scale is designed to address.
This is a closed-door virtual room for twelve to fifteen investors, founders, IBs, and licensing professionals actively working on healthcare IP commercialisation and cross-border market access. Not a panel. Not a webinar. A structured ninety-minute conversation among people who are in the middle of these transactions — structuring deals, advising on them, or evaluating them for capital deployment.
The room draws on TCR Healthcare's partnership with Genesis, which manages a curated portfolio of 1,000+ molecules available for licensing and brings active buy-side and sell-side licensing mandates to every conversation.
What the room will cover
→ What makes a healthcare licensing transaction structurally durable — across pharma, devices, health-tech, and bioscience — and where do deals most commonly break down before they close?
→ How should licensing revenue be valued by capital providers — what EBITDA quality tests apply, how is milestone revenue priced versus royalty revenue, and where is PE actively deploying in licensing-revenue healthcare businesses?
→ Cross-border market access: which corridors are generating the most active healthcare licensing activity right now — India–GCC, India–Israel, India–Europe — and what does a well-structured cross-border licensing deal look like in each?
→ Beyond pharma — device technology transfer, health-tech IP licensing, and bioscience platform commercialisation: where are the undercapitalised licensing opportunities in healthcare that the market has not yet organised around?
What you leave with
Every participant receives a post-room intelligence brief within 72 hours — licensing deal benchmarks, active mandate signals, cross-border market access intelligence, and capital deployment insights from the discussion. Exclusive to the room.
Who is in the room
Healthcare IBs and licensing transaction professionals | PE and growth equity professionals with active healthcare mandates | Pharma, device, and health-tech company licensing and BD leads | MNC healthcare corporate BD directors | Regulatory and IP advisory professionals | Capital providers evaluating licensing-revenue healthcare businesses
Participation is by invitation only. The room is composed- not open. Participants from Well Capitalised and Pulse Check are invited to continue the series here.
HOSTED BY
TCR Healthcare- a private capital coordination platform operating across India's healthcare and life sciences sector. Licensed to Scale is the third room in TCR's 2026 Healthcare Roundtable Series, convened in partnership with Genesis.
EVENT DETAILS BLOCK
📅 First Thursday · May 2026
🕐 90 Minutes
💻 Virtual · Google Meet
🔒 By Invitation Only · 12–15 Participants
📄 Post-Room Intelligence Report included
This is a private, invitation-only event hosted by The Capital Room (TCR). Registrations are reviewed before confirmation. All room discussions are confidential and not for public attribution.